
Chinese General Practice ›› 2023, Vol. 26 ›› Issue (08): 911-916.DOI: 10.12114/j.issn.1007-9572.2022.0660
Special Issue: 内分泌代谢性疾病最新文章合辑; 消化系统疾病最新文章合辑
• Original Research • Previous Articles Next Articles
Received:2022-09-11
Revised:2022-11-10
Published:2023-03-15
Online:2022-11-24
Contact:
DENG Xia, YUAN Guoyue
通讯作者:
邓霞, 袁国跃
作者简介:基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0660
| 组别 | 例数 | 性别(男/女) | 年龄(岁) | T2DM病程〔M(P25,P75),月〕 | 高血压病史〔n(%)〕 | 吸烟史〔n(%)〕 | 饮酒史〔n(%)〕 | BMI(kg/m2) | WHR〔M(P25,P75)〕 |
|---|---|---|---|---|---|---|---|---|---|
| 非NAFLD组 | 50 | 27/23 | 58.8±12.7 | 120(33,168) | 21(42.0) | 12(24.0) | 9(18.0) | 23.8±3.0 | 0.93(0.88,0.97) |
| NAFLD组 | 80 | 47/33 | 53.6±11.8 | 24(1,120) | 35(43.8) | 22(27.5) | 12(15.0) | 25.8±2.9 | 0.94(0.91,0.98) |
| 检验统计量值 | 0.283b | 2.359 | -3.545a | 0.038b | 0.195b | 0.204b | -3.884 | -1.077a | |
| P值 | 0.595 | 0.020 | <0.001 | 0.845 | 0.659 | 0.651 | <0.001 | 0.282 | |
| 组别 | SBP(mm Hg) | DBP〔M(P25,P75),mm Hg〕 | FPG(mmol/L) | 2 hPG(mmol/L) | FIns〔M(P25,P75),U/ml〕 | 2 hIns〔M(P25,P75),U/ml〕 | FCP(g/L) | 2 hCP〔M(P25,P75),g/L〕 | |
| 非NAFLD组 | 134±17 | 80(73,86) | 9.94±3.55 | 19.65±5.50 | 4.84(3.17,11.89) | 23.43(13.76,46.83) | 1.93±0.96 | 3.42(2.53,5.31) | |
| NAFLD组 | 134±17 | 80(72,90) | 10.26±3.03 | 18.90±4.63 | 8.35(5.18,13.33) | 30.00(17.81,52.99) | 2.66±1.12 | 5.35(3.50,7.63) | |
| 检验统计量值 | 0.089 | -0.062a | -0.540 | 0.837 | -2.508a | -2.070a | -3.811 | -3.718a | |
| P值 | 0.929 | 0.950 | 0.590 | 0.404 | 0.012 | 0.038 | <0.001 | <0.001 | |
| 组别 | HOMA-IR〔M(P25,P75)〕 | HOMA-β〔M(P25,P75)〕 | HbA1c(%) | TG〔M(P25,P75),mmol/L〕 | TC〔M(P25,P75),mmol/L〕 | HDL-C〔M(P25,P75),mmol/L〕 | LDL-C(mmol/L) | ||
| 非NAFLD组 | 2.47(1.58,4.21) | 17.22(8.26,49.21) | 9.62±2.13 | 1.56(1.12,2.12) | 4.64(4.23,5.55) | 1.09(0.93,1.31) | 2.85±0.80 | ||
| NAFLD组 | 3.64(2.56,4.98) | 26.86(14.98,45.50) | 9.50±2.03 | 2.24(1.51,3.72) | 4.83(4.14,6.01) | 1.06(0.87,1.23) | 2.91±0.84 | ||
| 检验统计量值 | -2.852a | -1.847a | 0.316 | -3.759a | -0.658a | -1.146a | -0.416 | ||
| P值 | 0.004 | 0.065 | 0.929 | <0.010 | 0.511 | 0.252 | 0.678 | ||
| 组别 | ALT〔M(P25,P75),U/L〕 | AST〔M(P25,P75),U/L〕 | SUA(μmol/L) | Scr〔M(P25,P75),mol/L〕 | BUN〔M(P25,P75),mmol/L〕 | EDA〔M(P25,P75),ng/L〕 | |||
| 非NAFLD组 | 15.10(10.03,22.00) | 14.30(12.10,19.65) | 273.07±89.84 | 58.10(50.00,72.98) | 5.50(4.49,6.62) | 309.13(235.39,402.56) | |||
| NAFLD组 | 27.45(14.30,43.43) | 19.75(13.50,29.10) | 314.05±88.76 | 58.60(51.25,68.65) | 4.95(4.28,5.72) | 363.17(312.50,437.17) | |||
| 检验统计量值 | -3.963a | -2.759a | -2.549 | -0.502a | -2.393a | -2.859a | |||
| P值 | <0.010 | 0.006 | 0.012 | 0.615 | 0.017 | 0.004 |
Table 1 Comparison of baseline data between T2DM patients with and without ultrasound-detected NAFLD
| 组别 | 例数 | 性别(男/女) | 年龄(岁) | T2DM病程〔M(P25,P75),月〕 | 高血压病史〔n(%)〕 | 吸烟史〔n(%)〕 | 饮酒史〔n(%)〕 | BMI(kg/m2) | WHR〔M(P25,P75)〕 |
|---|---|---|---|---|---|---|---|---|---|
| 非NAFLD组 | 50 | 27/23 | 58.8±12.7 | 120(33,168) | 21(42.0) | 12(24.0) | 9(18.0) | 23.8±3.0 | 0.93(0.88,0.97) |
| NAFLD组 | 80 | 47/33 | 53.6±11.8 | 24(1,120) | 35(43.8) | 22(27.5) | 12(15.0) | 25.8±2.9 | 0.94(0.91,0.98) |
| 检验统计量值 | 0.283b | 2.359 | -3.545a | 0.038b | 0.195b | 0.204b | -3.884 | -1.077a | |
| P值 | 0.595 | 0.020 | <0.001 | 0.845 | 0.659 | 0.651 | <0.001 | 0.282 | |
| 组别 | SBP(mm Hg) | DBP〔M(P25,P75),mm Hg〕 | FPG(mmol/L) | 2 hPG(mmol/L) | FIns〔M(P25,P75),U/ml〕 | 2 hIns〔M(P25,P75),U/ml〕 | FCP(g/L) | 2 hCP〔M(P25,P75),g/L〕 | |
| 非NAFLD组 | 134±17 | 80(73,86) | 9.94±3.55 | 19.65±5.50 | 4.84(3.17,11.89) | 23.43(13.76,46.83) | 1.93±0.96 | 3.42(2.53,5.31) | |
| NAFLD组 | 134±17 | 80(72,90) | 10.26±3.03 | 18.90±4.63 | 8.35(5.18,13.33) | 30.00(17.81,52.99) | 2.66±1.12 | 5.35(3.50,7.63) | |
| 检验统计量值 | 0.089 | -0.062a | -0.540 | 0.837 | -2.508a | -2.070a | -3.811 | -3.718a | |
| P值 | 0.929 | 0.950 | 0.590 | 0.404 | 0.012 | 0.038 | <0.001 | <0.001 | |
| 组别 | HOMA-IR〔M(P25,P75)〕 | HOMA-β〔M(P25,P75)〕 | HbA1c(%) | TG〔M(P25,P75),mmol/L〕 | TC〔M(P25,P75),mmol/L〕 | HDL-C〔M(P25,P75),mmol/L〕 | LDL-C(mmol/L) | ||
| 非NAFLD组 | 2.47(1.58,4.21) | 17.22(8.26,49.21) | 9.62±2.13 | 1.56(1.12,2.12) | 4.64(4.23,5.55) | 1.09(0.93,1.31) | 2.85±0.80 | ||
| NAFLD组 | 3.64(2.56,4.98) | 26.86(14.98,45.50) | 9.50±2.03 | 2.24(1.51,3.72) | 4.83(4.14,6.01) | 1.06(0.87,1.23) | 2.91±0.84 | ||
| 检验统计量值 | -2.852a | -1.847a | 0.316 | -3.759a | -0.658a | -1.146a | -0.416 | ||
| P值 | 0.004 | 0.065 | 0.929 | <0.010 | 0.511 | 0.252 | 0.678 | ||
| 组别 | ALT〔M(P25,P75),U/L〕 | AST〔M(P25,P75),U/L〕 | SUA(μmol/L) | Scr〔M(P25,P75),mol/L〕 | BUN〔M(P25,P75),mmol/L〕 | EDA〔M(P25,P75),ng/L〕 | |||
| 非NAFLD组 | 15.10(10.03,22.00) | 14.30(12.10,19.65) | 273.07±89.84 | 58.10(50.00,72.98) | 5.50(4.49,6.62) | 309.13(235.39,402.56) | |||
| NAFLD组 | 27.45(14.30,43.43) | 19.75(13.50,29.10) | 314.05±88.76 | 58.60(51.25,68.65) | 4.95(4.28,5.72) | 363.17(312.50,437.17) | |||
| 检验统计量值 | -3.963a | -2.759a | -2.549 | -0.502a | -2.393a | -2.859a | |||
| P值 | <0.010 | 0.006 | 0.012 | 0.615 | 0.017 | 0.004 |
| 指标 | 年龄 | BMI | WHR | SBP | DBP | FPG | 2 hPG | FIns | 2 hIns | FCP | 2 hCP | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| r(rs)值 | 0.222 | 0.093 | -0.113a | 0.094 | -0.020a | -0.104 | 0.040 | 0.224a | 0.207a | 0.069 | 0.149a | |
| P值 | 0.011 | 0.291 | 0.199 | 0.286 | 0.823 | 0.239 | 0.653 | 0.010 | 0.018 | 0.439 | 0.091 | |
| 指标 | HOMA-IR | HOMA-β | HbA1c | TG | TC | HDL-C | LDL-C | ALT | AST | SUA | Scr | BUN |
| r(rs)值 | 0.210a | 0.173a | 0.017 | 0.038a | 0.116a | 0.089a | 0.089 | 0.158a | 0.251a | 0.103 | 0.187a | 0.029a |
| P值 | 0.017 | 0.049 | 0.844 | 0.669 | 0.188 | 0.315 | 0.316 | 0.072 | 0.004 | 0.244 | 0.033 | 0.747 |
Table 2 Correlation analysis of serum ectodysplasin A with clinical and biochemical indices in T2DM patients
| 指标 | 年龄 | BMI | WHR | SBP | DBP | FPG | 2 hPG | FIns | 2 hIns | FCP | 2 hCP | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| r(rs)值 | 0.222 | 0.093 | -0.113a | 0.094 | -0.020a | -0.104 | 0.040 | 0.224a | 0.207a | 0.069 | 0.149a | |
| P值 | 0.011 | 0.291 | 0.199 | 0.286 | 0.823 | 0.239 | 0.653 | 0.010 | 0.018 | 0.439 | 0.091 | |
| 指标 | HOMA-IR | HOMA-β | HbA1c | TG | TC | HDL-C | LDL-C | ALT | AST | SUA | Scr | BUN |
| r(rs)值 | 0.210a | 0.173a | 0.017 | 0.038a | 0.116a | 0.089a | 0.089 | 0.158a | 0.251a | 0.103 | 0.187a | 0.029a |
| P值 | 0.017 | 0.049 | 0.844 | 0.669 | 0.188 | 0.315 | 0.316 | 0.072 | 0.004 | 0.244 | 0.033 | 0.747 |
| 指标 | β | 95%CI | SE | 标准化β | t值 | P值 |
|---|---|---|---|---|---|---|
| 常量 | 502.738 | (203.176,802.300) | 151.361 | — | 3.321 | 0.001 |
| 年龄 | 1.957 | (0.412,3.502) | 0.781 | 0.214 | 2.506 | 0.013 |
| WHR | -328.845 | (-638.903,-18.788) | 156.664 | -0.175 | -2.099 | 0.038 |
| 2 hIns | 0.523 | (0.036,1.011) | 0.246 | 0.181 | 2.125 | 0.036 |
| AST | 2.148 | (0.520,3.776) | 0.823 | 0.220 | 2.611 | 0.010 |
Table 3 Multiple linear regression analysis of factors associated with serum ectodysplasin A in T2DM
| 指标 | β | 95%CI | SE | 标准化β | t值 | P值 |
|---|---|---|---|---|---|---|
| 常量 | 502.738 | (203.176,802.300) | 151.361 | — | 3.321 | 0.001 |
| 年龄 | 1.957 | (0.412,3.502) | 0.781 | 0.214 | 2.506 | 0.013 |
| WHR | -328.845 | (-638.903,-18.788) | 156.664 | -0.175 | -2.099 | 0.038 |
| 2 hIns | 0.523 | (0.036,1.011) | 0.246 | 0.181 | 2.125 | 0.036 |
| AST | 2.148 | (0.520,3.776) | 0.823 | 0.220 | 2.611 | 0.010 |
| 变量 | 赋值 |
|---|---|
| 发生NAFLD | 是=1,否=0 |
| EDA | 实测值 |
| 高血压病史 | 有=1,无=0 |
| 吸烟史 | 有=1,无=0 |
| 饮酒史 | 有=1,无=0 |
| 性别 | 男=1,女=2 |
| 年龄 | 实测值 |
| T2DM病程 | 实测值 |
| BMI | 实测值 |
| WHR | 实测值 |
Table 4 Assignment for influencing factors of NAFLD in T2DM analyzed using multivariate Logistic regression
| 变量 | 赋值 |
|---|---|
| 发生NAFLD | 是=1,否=0 |
| EDA | 实测值 |
| 高血压病史 | 有=1,无=0 |
| 吸烟史 | 有=1,无=0 |
| 饮酒史 | 有=1,无=0 |
| 性别 | 男=1,女=2 |
| 年龄 | 实测值 |
| T2DM病程 | 实测值 |
| BMI | 实测值 |
| WHR | 实测值 |
| 指标 | β | SE | Wald χ2值 | P值 | OR值 | 95%CI |
|---|---|---|---|---|---|---|
| 未校正模型 | 0.004 | 0.002 | 5.421 | 0.020 | 1.004 | (1.001,1.008) |
| 模型1 | 0.005 | 0.002 | 7.436 | 0.006 | 1.005 | (1.001,1.009) |
| 模型2 | 0.006 | 0.002 | 7.074 | 0.008 | 1.006 | (1.001,1.010) |
| 模型3 | 0.006 | 0.002 | 7.249 | 0.007 | 1.006 | (1.002,1.010) |
Table 5 Multivariate Logistic regression analysis of factors affecting NAFLD in T2DM patients
| 指标 | β | SE | Wald χ2值 | P值 | OR值 | 95%CI |
|---|---|---|---|---|---|---|
| 未校正模型 | 0.004 | 0.002 | 5.421 | 0.020 | 1.004 | (1.001,1.008) |
| 模型1 | 0.005 | 0.002 | 7.436 | 0.006 | 1.005 | (1.001,1.009) |
| 模型2 | 0.006 | 0.002 | 7.074 | 0.008 | 1.006 | (1.001,1.010) |
| 模型3 | 0.006 | 0.002 | 7.249 | 0.007 | 1.006 | (1.002,1.010) |
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
刘君,杨艳君,韩伟. 尿微量白蛋白与尿肌酐比值对2型糖尿病合并非酒精性脂肪肝的影响[J]. 安徽医药,2021,25(8):1656-1659.
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
American Diabetes Association. Diagnosis and classification of diabetes mellitus[J]. Diabetes Care,2014,37(Suppl 1):S81-90. DOI:10.2337/dc14-s081.
|
| [11] |
中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年1月修订)[J]. 中华内科杂志,2010,49(3):275-278. DOI:10.3760/cma.j.issn.0578-1426.2010.03.029.
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
卢亚男,刘丽俊,李伟. GA/HbA1c比值与2型糖尿病合并非酒精性脂肪肝相关[J]. 基础医学与临床,2020,40(12):1636-1639. DOI:10.16352/j.issn.1001-6325.2020.12.006.
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [1] | AN Yanhong, WANG Shidong, LI Xiaoran, GUO Jiayang, WANG Zhe, SHA Peilin, MENG Yijun, LI Xiaoxuan, SHI Xue, YU Zexing, XIAO Yonghua. Study on Risk Factors and Nomogram Prediction Model for Diabetic Kidney Disease: Based on Contrast-enhanced Ultrasound Technology [J]. Chinese General Practice, 2026, 29(21): 2995-3003. |
| [2] | SONG Zhenzhen, CHEN Yang, WANG Jiwen, LIU Huishan, SHEN Simeng, SUN Ying, CHEN Xing. Study of Maternal Risk Factors Associated with Neonatal Asphyxia in Late Preterm and Term Infants [J]. Chinese General Practice, 2026, 29(20): 2874-2878. |
| [3] | YANG Xiaofeng, LI Xianwen, WU Yanfeng, ZHANG Qian, CHEN Juan, ZHAO Fengjiao. Association of Serum Vascular Endothelial Cadherin Levels with the Risk of Post-stroke Cognitive Impairment in Patients with Acute Ischemic Stroke [J]. Chinese General Practice, 2026, 29(20): 2867-2873. |
| [4] | GE Dan, WANG Zhi, DING Qun, GUO Tonglan, XU Tongdao. Relationship between Remnant Cholesterol and Non-alcoholic Fatty Liver Disease as well as Progressive Liver Fibrosis in Patients with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(20): 2854-2859. |
| [5] | ZHAO Huili, LU Lina, ZHUO Ya, WANG Xin. Clinical Characteristics and Risk Factors for Recurrence of Cryptogenic Organizing Pneumonia [J]. Chinese General Practice, 2026, 29(19): 2648-2655. |
| [6] | HUANG Minshan, CHEN Hang, LI Liya, YANG Taiming, CHEN Lifang, LI Shenchao, REN Li, WANG Hui, LI Mingke, WANG Xianmei, WANG Da, WAN Ying, HE Yule, ZHOU Qingqing, LI Yu, LI Mengwei, LU Lihong, LUO Yifan, MA Lanqing. The Current Status of Awareness and Influencing Factors Analysis of Metabolic-associated Fatty Liver Disease among the General Population in Multiple Regions of Yunnan [J]. Chinese General Practice, 2026, 29(17): 2347-2353. |
| [7] | ZHEN Rui, GU Xufang, GAO Shengwei, ZHANG Bowen, REN Zhenjuan, YANG Ruixuan. Burden of Cardiovascular Diseases Attributable to Metabolic Risk Factors in China 1990—2021 and Projected Trends from 2022 to 2035 [J]. Chinese General Practice, 2026, 29(15): 2077-2083. |
| [8] | LIU Tianyuan, SANG Wanyue, PENG Jiping, CHENG Siyi, HUANG Yiyi, LI Ouwen, JIANG Hong, ZHOU Xiaoya. Correlation Analysis between Neurofilament Light Chain and the Risk of Left Ventricular Hypertrophy in Patients with Nocturnal Hypertension [J]. Chinese General Practice, 2026, 29(15): 2014-2021. |
| [9] | CHEN Yiming, HUANG Yiling, JI Fei, LYU Ling, HUANG Yu, WU Zeyu, HANG Qiqi, PING Fan, YANG Meng. Hepatic-glycemic Interdependence: the Bidirectional Relationship between Type 2 Diabetes and MASLD and Emerging Therapeutic Strategies [J]. Chinese General Practice, 2026, 29(12): 1497-1504. |
| [10] | HU Jiaqi, LI Duan, FANG Hao, FAN Xingying, DU Wei, ZHOU Hanni. Study on Predictive Model of Non-genetic Risk Factors for Hyperuricemia in a Physical Examination Cohort [J]. Chinese General Practice, 2026, 29(10): 1324-1333. |
| [11] | ZHANG Qiuyu, HU Xiaoyong, TANG Rui, LI Hongjian. Correlation between Chinese Visceral Adiposity Index and Nocturnal Hypertension in Young and Middle-aged People [J]. Chinese General Practice, 2026, 29(07): 872-878. |
| [12] | LEI Yingying, ZHENG Siying, WANG Wenxin, JIANG Hong. Prevalence Trend and Prediction of Hypertensive Heart Disease in the World and China from 1990 to 2021 [J]. Chinese General Practice, 2026, 29(05): 641-648. |
| [13] | LI Jixin, QIU Linjie, REN Yan, WANG Wenru, YANG Zhenyu, LIU Fengzhao, LI Meijie, LI Wenjie, ZHANG Jin. Correlation of Muscle-fat Ratio with Non-obese Hyperuricaemia and the Predictive Value [J]. Chinese General Practice, 2026, 29(01): 84-90. |
| [14] | MI Lingyu, CHEN Lianxin, GAO Hengbo, WANG Bincheng. Predictive Value of Triglyceride-glucose Index for Prognosis in Patients with Pulmonary Embolism [J]. Chinese General Practice, 2025, 28(35): 4421-4429. |
| [15] | WANG Biyou, GAO Ying, YOU Junfang, LIU Li, ZHANG Qing, SU Haiyan. Canonical Correlation Analysis of Lipid Ratios and Inflammatory Markers in Individuals at Risk of Cardiovascular Disease [J]. Chinese General Practice, 2025, 28(33): 4132-4139. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||